Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Target Therapy and Immunotherapy for Gastric Cancer - Recent Updates

Author(s): Barani Karikalan* and Srikumar Chakravarthi

Volume 18, Issue 3, 2022

Published on: 28 June, 2022

Page: [202 - 208] Pages: 7

DOI: 10.2174/1573394718666220418095954

Price: $65

Abstract

Gastric cancer, with more than 1 million cases all over the globe, is a leading contributor to cancer mortality. In the recent past, the evolution of target therapies and the refining of the already existing chemotherapy have widened the therapeutic choices for advanced gastric cancer to increase survival. In addition, more studies have been conducted all over the globe to extensively evaluate epigenomic and genomic heterogeneity of gastric cancer, leading to the recognition of new sensitive and specific prognostic and predictive biomarkers and the development of new molecular tumor classifications based on their molecular profiling. But, many clinical studies aimed at evaluating the efficiency of certain new molecular targets gave negative results. Hence, it is vital to further study the molecular features of subtypes of gastric carcinoma for the purpose of identifying new tools for selecting responsive tumor subtypes for future trials. This review provides an overview of recent developments of target therapy and immunotherapy in advanced gastric cancer.

Keywords: Gastric, cancer, carcinoma, target, molecular, therapy.

« Previous Next »
Graphical Abstract

[1]
Rawla P, Barsouk A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol 2019; 14(1): 26-38.
[http://dx.doi.org/10.5114/pg.2018.80001] [PMID: 30944675]
[2]
Chakravarthi S, Karikalan B. α-fetoprotein producing gastric cancers - A quick review. Acad J Cancer Res 2020; 13(2): 18-21.
[3]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[4]
Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64(1): 31-49.
[http://dx.doi.org/10.1111/apm.1965.64.1.31] [PMID: 14320675]
[5]
Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res 2011; 17(9): 2693-701.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2203] [PMID: 21430069]
[6]
Rugge M, Genta RM, Di Mario F, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol 2017; 15(12): 1833-43.
[http://dx.doi.org/10.1016/j.cgh.2017.05.023] [PMID: 28532700]
[7]
Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: From the laboratory to clinical practice. Ann Oncol 2003; 14(12): 1705-13.
[http://dx.doi.org/10.1093/annonc/mdg486] [PMID: 14630673]
[8]
Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumours of the digestive system. IARC-Press 2010.
[9]
Marano L, Polom K, Patriti A, et al. Surgical management of advanced gastric cancer: An evolving issue. Eur J Surg Oncol 2016; 42(1): 18-27.
[http://dx.doi.org/10.1016/j.ejso.2015.10.016] [PMID: 26632080]
[10]
Pellino A, Riello E, Nappo F, et al. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J Gastroenterol 2019; 25(38): 5773-88.
[http://dx.doi.org/10.3748/wjg.v25.i38.5773] [PMID: 31636471]
[11]
Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22(42): 6570-8.
[http://dx.doi.org/10.1038/sj.onc.1206779] [PMID: 14528282]
[12]
Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015; 18(3): 476-84.
[http://dx.doi.org/10.1007/s10120-014-0402-y] [PMID: 25038874]
[13]
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687-97.
[http://dx.doi.org/10.1016/S0140-6736(10)61121-X] [PMID: 20728210]
[14]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513(7517): 202-9.
[http://dx.doi.org/10.1038/nature13480] [PMID: 25079317]
[15]
Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer 2016; 139(12): 2859-64.
[http://dx.doi.org/10.1002/ijc.30408] [PMID: 27578417]
[16]
Janjigian YY, Sanchez-Vega F, Tuvy Y, et al. Emergence of RTK/RAS/PIK3 pathway alterations in trastuzumab-refractory HER-2 positive esophagogastric (EG) tumours. J Clin Oncol 2016; 34(15): 11608.
[17]
Arienti C, Pignatta S, Tesei A. Epidermal growth factor receptor family and its role in gastric cancer. Front Oncol 2019; 9: 1308.
[http://dx.doi.org/10.3389/fonc.2019.01308] [PMID: 31850207]
[18]
Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 2013; 14(6): 481-9.
[http://dx.doi.org/10.1016/S1470-2045(13)70096-2] [PMID: 23594787]
[19]
Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011; 22(6): 1358-66.
[http://dx.doi.org/10.1093/annonc/mdq591] [PMID: 21119032]
[20]
Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009; 100(2): 298-304.
[http://dx.doi.org/10.1038/sj.bjc.6604861] [PMID: 19127259]
[21]
Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: Results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011; 11(1): 509.
[http://dx.doi.org/10.1186/1471-2407-11-509] [PMID: 22152101]
[22]
Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol 2013; 14(6): 490-9.
[http://dx.doi.org/10.1016/S1470-2045(13)70102-5] [PMID: 23594786]
[23]
Satoh T, Lee KH, Rha SY, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer 2015; 18(4): 824-32.
[http://dx.doi.org/10.1007/s10120-014-0420-9]
[24]
Trusolino L, Bertotti A, Comoglio PM. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11(12): 834-48.
[http://dx.doi.org/10.1038/nrm3012] [PMID: 21102609]
[25]
Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008; 265(2): 258-69.
[http://dx.doi.org/10.1016/j.canlet.2008.02.049] [PMID: 18395971]
[26]
Shah MA, Bang YJ, Lordick F, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric randomized clinical trial. JAMA Oncol 2017; 3(5): 620-7.
[http://dx.doi.org/10.1001/jamaoncol.2016.5580] [PMID: 27918764]
[27]
Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(11): 1467-82.
[http://dx.doi.org/10.1016/S1470-2045(17)30566-1] [PMID: 28958504]
[28]
El Darsa H, El Sayed R, Abdel-Rahman O. MET inhibitors for the treatment of gastric cancer: What’s their potential? J Exp Pharmacol 2020; 12: 349-61.
[http://dx.doi.org/10.2147/JEP.S242958] [PMID: 33116950]
[29]
Su X, Zhan P, Gavine PR, et al. FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study. Br J Cancer 2014; 110(4): 967-75.
[http://dx.doi.org/10.1038/bjc.2013.802] [PMID: 24457912]
[30]
Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 2012; 43(10): 1559-66.
[http://dx.doi.org/10.1016/j.humpath.2011.12.002] [PMID: 22440694]
[31]
Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012; 106(4): 727-32.
[http://dx.doi.org/10.1038/bjc.2011.603] [PMID: 22240789]
[32]
Xie L, Su X, Zhang L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013; 19(9): 2572-83.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-3898] [PMID: 23493349]
[33]
Van Cutsem E, Bang YJ, Mansoor W, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol 2017; 28(6): 1316-24.
[http://dx.doi.org/10.1093/annonc/mdx107] [PMID: 29177434]
[34]
Yashiro M, Matsuoka T. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. World J Gastroenterol 2016; 22(8): 2415-23.
[http://dx.doi.org/10.3748/wjg.v22.i8.2415] [PMID: 26937130]
[35]
Hierro C, Alsina M, Sánchez M, Serra V, Rodon J, Tabernero J. Targeting the fibroblast growth factor receptor 2 in gastric cancer: Promise or pitfall? Ann Oncol 2018; 29(7): 1605.
[http://dx.doi.org/10.1093/annonc/mdx800] [PMID: 29300805]
[36]
Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998; 141(7): 1539-50.
[http://dx.doi.org/10.1083/jcb.141.7.1539] [PMID: 9647647]
[37]
Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol 2006; 208(5): 633-42.
[http://dx.doi.org/10.1002/path.1922] [PMID: 16435283]
[38]
Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008; 14(23): 7624-34.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1547] [PMID: 19047087]
[39]
Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 2017; 10(1): 105.
[http://dx.doi.org/10.1186/s13045-017-0473-4] [PMID: 28494772]
[40]
Schuler MH, Zvirbule Z, Lordick F, et al. Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. ASCO Meet Abstr 2013; 31: 4080.
[41]
Sahin U, Al-Batran S-E, Hozaeel W, et al. IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial. ASCO Meet Abstr 2015; 33: e15079.
[42]
Trarbach T, Schuler M, Zvirbule Z, et al. 636P. Efficacy and safety of multiple doses of IMAB362 in patients with advanced gastroesophageal cancer: Results of a phase II study. Ann Oncol 2014; 25(4) (Suppl.): iv218.
[http://dx.doi.org/10.1093/annonc/mdu334.21]
[43]
Al-Batran S-E, Schuler M, Zvirbule Z, et al. LBA-06. IMAB362: A novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer. Ann Oncol 2016; 27(2) (Suppl.): ii141-2.
[http://dx.doi.org/10.1093/annonc/mdw237.06]
[44]
Al-Batran S, Schuler M, Zvirbule Z, et al. FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. ASCO Meet Abstr 2016; 34: LBA4001.
[45]
Shu Y, Zhang W, Hou Q, et al. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nat Commun 2018; 9(1): 2447.
[http://dx.doi.org/10.1038/s41467-018-04907-0] [PMID: 29961079]
[46]
Zhang J, Dong R, Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chinese J Cancer Res 2020; 32(2): 263-70.
[http://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.13]
[47]
Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: Are we making headway? Nat Rev Clin Oncol 2018; 15(5): 273-91.
[http://dx.doi.org/10.1038/nrclinonc.2018.28] [PMID: 29508857]
[48]
Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013; 306: 162-8.
[http://dx.doi.org/10.1016/j.tox.2013.02.014] [PMID: 23466500]
[49]
Xiong J, Li Z, Zhang Y, et al. PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN. Oncol Rep 2016; 36(4): 1819-28.
[http://dx.doi.org/10.3892/or.2016.5030] [PMID: 27572739]
[50]
Jin P, Sun L. Tu1968 the effect of a novel Akt inhibitor MK-2206 on proliferation and chemosensitivity of gastric cancer. Gastroenterology 2015; 148(4) (Suppl. 1): S948-9.
[http://dx.doi.org/10.1016/S0016-5085(15)33235-2]
[51]
Hu M, Zhu S, Xiong S, Xue X, Zhou X. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review). Oncol Rep 2019; 41(3): 1439-54.
[http://dx.doi.org/10.3892/or.2019.6962] [PMID: 30628706]
[52]
Liu Y, Sun S, Li J, Yu D. Targeting the PI3K/AKT pathway for the treatment of gastric cancer. Chemotherapy 2014; 2014(3): 1.
[53]
Sexton R, Mahdi Z, Chaudhury R, et al. Targeting nuclear exporter protein XPO1/CRM1 in gastric cancer. Int J Mol Sci 2019; 20(19): 4826.
[http://dx.doi.org/10.3390/ijms20194826] [PMID: 31569391]
[54]
Soares HP, Kim RD, Almhanna K, Willians-Elson I, Kothari N, Mahipal A. An investigator sponsored phase Ia/Ib trial of selinexor in combination with irinotecan in patients with adenocarcinoma of stomach and distal esophagus. J Clin Oncol 2016; 34(4) (Suppl.): TPS176-6.
[55]
Kawazoe A, Kuwata T, Kuboki Y, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer 2017; 20(3): 407-15.
[http://dx.doi.org/10.1007/s10120-016-0631-3] [PMID: 27629881]
[56]
Böger C, Behrens H-M, Mathiak M, Krüger S, Kalthoff H, Röcken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016; 7(17): 24269-83.
[http://dx.doi.org/10.18632/oncotarget.8169]
[57]
Ribas A. Releasing the Brakes on Cancer Immunotherapy. N Engl J Med 2015; 373(16): 1490-2.
[http://dx.doi.org/10.1056/NEJMp1510079] [PMID: 26348216]
[58]
Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer 2018; 6(1): 35. [PMC free article]. [PubMed]. [Google Scholar].
[http://dx.doi.org/10.1186/s40425-018-0342-x]
[59]
Wang L, Zhang Q, Ni S, et al. Programmed death-ligand 1 expression in gastric cancer: Correlation with mismatch repair deficiency and HER2-negative status. Cancer Med 2018; 7(6): 2612-20.
[http://dx.doi.org/10.1002/cam4.1502] [PMID: 29673110]
[60]
Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018; 4: e180013. [PMC free article]. [PubMed]. [Google Scholar].
[61]
Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717-26.
[62]
Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 2018; 29: 2052-60. [PMC free article]. [PubMed]. [Google Scholar].
[63]
Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol 2019; 10: 1337.
[http://dx.doi.org/10.3389/fimmu.2019.01337] [PMID: 31258527]
[64]
Derks S, Liao X, Chiaravalli AM, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget 2016; 7(22): 32925-32.
[http://dx.doi.org/10.18632/oncotarget.9076] [PMID: 27147580]
[65]
Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 2018; 24(9): 1449-58.
[http://dx.doi.org/10.1038/s41591-018-0101-z] [PMID: 30013197]

Rights & Permissions Print Cite
Article Metrics
8
© 2024 Bentham Science Publishers | Privacy Policy